Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency

Wohaib Hasan, Pmg Bouloux, T. Cowen, P. Coskeran, E. Elliot, P. S. Barnett

Research output: Contribution to journalArticle

Abstract

We have previously demonstrated that reduced sweating is coincident with a decrease in the functional innervation of eccrine sweat glands in adults with growth hormone deficiency (GHD). The aim of this study was to examine the effect of treatment with recombinant human growth hormone (GH) for 6-12 months on the morphology, innervation and function of sweat glands. Twenty-one patients with GHD and twelve control individuals were studied. Forearm skin biopsies were processed for histochemistry and immunohistochemistry with acetylcholinesterase (AChE), the neuropeptide vasoactive intestinal polypeptide (VIP) and the general neuronal marker protein gene product 9.5 (PGP). Acinar size and periacinar innervation of sweat glands were measured by image analysis. Sweat production was measured following pilocarpine iontophoresis. The rate of sweating was initially reduced in patients with GHD, but increased by 15% following treatment with GH. The rate of sweating following GH treatment was not significantly different from the rate in controls; in female patients with GHD, the rate of sweating increased by 54% (analysis of variance, P <0.003). AChE histochemical staining (AChE-HS) of skin biopsies from patients with GHD increased by 61% (P <0.001) following GH treatment, to reach control values; in female patients with GHD, the increase in AChE-HS was 71% (P <0.001). VIP-immunoreactivity (VIP-IR) increased by 30% after GH treatment in patients with GHD, again reaching control values. In patients with GHD, PGP-IR did not change significantly following GH treatment. In conclusion, GH treatment of patients with GHD tends to normalize sweat gland function via sympathetic innervation. This effect is more marked in females.

Original languageEnglish (US)
Pages (from-to)130
Number of pages1
JournalEndocrinology and Metabolism, Supplement
Volume3
Issue numberSUPPL. A
StatePublished - 1996
Externally publishedYes

Fingerprint

Sweat Glands
Growth Hormone
Sweating
Acetylcholinesterase
Vasoactive Intestinal Peptide
Therapeutics
Eccrine Glands
Biopsy
Iontophoresis
Skin
Pilocarpine
Human Growth Hormone
Sweat
Neuropeptides

ASJC Scopus subject areas

  • Endocrinology

Cite this

Hasan, W., Bouloux, P., Cowen, T., Coskeran, P., Elliot, E., & Barnett, P. S. (1996). Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency. Endocrinology and Metabolism, Supplement, 3(SUPPL. A), 130.

Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency. / Hasan, Wohaib; Bouloux, Pmg; Cowen, T.; Coskeran, P.; Elliot, E.; Barnett, P. S.

In: Endocrinology and Metabolism, Supplement, Vol. 3, No. SUPPL. A, 1996, p. 130.

Research output: Contribution to journalArticle

Hasan, W, Bouloux, P, Cowen, T, Coskeran, P, Elliot, E & Barnett, PS 1996, 'Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency', Endocrinology and Metabolism, Supplement, vol. 3, no. SUPPL. A, pp. 130.
Hasan, Wohaib ; Bouloux, Pmg ; Cowen, T. ; Coskeran, P. ; Elliot, E. ; Barnett, P. S. / Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency. In: Endocrinology and Metabolism, Supplement. 1996 ; Vol. 3, No. SUPPL. A. pp. 130.
@article{f59e3e06e23542f6bf05803a1fc6d6d1,
title = "Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency",
abstract = "We have previously demonstrated that reduced sweating is coincident with a decrease in the functional innervation of eccrine sweat glands in adults with growth hormone deficiency (GHD). The aim of this study was to examine the effect of treatment with recombinant human growth hormone (GH) for 6-12 months on the morphology, innervation and function of sweat glands. Twenty-one patients with GHD and twelve control individuals were studied. Forearm skin biopsies were processed for histochemistry and immunohistochemistry with acetylcholinesterase (AChE), the neuropeptide vasoactive intestinal polypeptide (VIP) and the general neuronal marker protein gene product 9.5 (PGP). Acinar size and periacinar innervation of sweat glands were measured by image analysis. Sweat production was measured following pilocarpine iontophoresis. The rate of sweating was initially reduced in patients with GHD, but increased by 15{\%} following treatment with GH. The rate of sweating following GH treatment was not significantly different from the rate in controls; in female patients with GHD, the rate of sweating increased by 54{\%} (analysis of variance, P <0.003). AChE histochemical staining (AChE-HS) of skin biopsies from patients with GHD increased by 61{\%} (P <0.001) following GH treatment, to reach control values; in female patients with GHD, the increase in AChE-HS was 71{\%} (P <0.001). VIP-immunoreactivity (VIP-IR) increased by 30{\%} after GH treatment in patients with GHD, again reaching control values. In patients with GHD, PGP-IR did not change significantly following GH treatment. In conclusion, GH treatment of patients with GHD tends to normalize sweat gland function via sympathetic innervation. This effect is more marked in females.",
author = "Wohaib Hasan and Pmg Bouloux and T. Cowen and P. Coskeran and E. Elliot and Barnett, {P. S.}",
year = "1996",
language = "English (US)",
volume = "3",
pages = "130",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "SUPPL. A",

}

TY - JOUR

T1 - Recombinant growth hormone improves sweat gland function in adults with growth hormone deficiency

AU - Hasan, Wohaib

AU - Bouloux, Pmg

AU - Cowen, T.

AU - Coskeran, P.

AU - Elliot, E.

AU - Barnett, P. S.

PY - 1996

Y1 - 1996

N2 - We have previously demonstrated that reduced sweating is coincident with a decrease in the functional innervation of eccrine sweat glands in adults with growth hormone deficiency (GHD). The aim of this study was to examine the effect of treatment with recombinant human growth hormone (GH) for 6-12 months on the morphology, innervation and function of sweat glands. Twenty-one patients with GHD and twelve control individuals were studied. Forearm skin biopsies were processed for histochemistry and immunohistochemistry with acetylcholinesterase (AChE), the neuropeptide vasoactive intestinal polypeptide (VIP) and the general neuronal marker protein gene product 9.5 (PGP). Acinar size and periacinar innervation of sweat glands were measured by image analysis. Sweat production was measured following pilocarpine iontophoresis. The rate of sweating was initially reduced in patients with GHD, but increased by 15% following treatment with GH. The rate of sweating following GH treatment was not significantly different from the rate in controls; in female patients with GHD, the rate of sweating increased by 54% (analysis of variance, P <0.003). AChE histochemical staining (AChE-HS) of skin biopsies from patients with GHD increased by 61% (P <0.001) following GH treatment, to reach control values; in female patients with GHD, the increase in AChE-HS was 71% (P <0.001). VIP-immunoreactivity (VIP-IR) increased by 30% after GH treatment in patients with GHD, again reaching control values. In patients with GHD, PGP-IR did not change significantly following GH treatment. In conclusion, GH treatment of patients with GHD tends to normalize sweat gland function via sympathetic innervation. This effect is more marked in females.

AB - We have previously demonstrated that reduced sweating is coincident with a decrease in the functional innervation of eccrine sweat glands in adults with growth hormone deficiency (GHD). The aim of this study was to examine the effect of treatment with recombinant human growth hormone (GH) for 6-12 months on the morphology, innervation and function of sweat glands. Twenty-one patients with GHD and twelve control individuals were studied. Forearm skin biopsies were processed for histochemistry and immunohistochemistry with acetylcholinesterase (AChE), the neuropeptide vasoactive intestinal polypeptide (VIP) and the general neuronal marker protein gene product 9.5 (PGP). Acinar size and periacinar innervation of sweat glands were measured by image analysis. Sweat production was measured following pilocarpine iontophoresis. The rate of sweating was initially reduced in patients with GHD, but increased by 15% following treatment with GH. The rate of sweating following GH treatment was not significantly different from the rate in controls; in female patients with GHD, the rate of sweating increased by 54% (analysis of variance, P <0.003). AChE histochemical staining (AChE-HS) of skin biopsies from patients with GHD increased by 61% (P <0.001) following GH treatment, to reach control values; in female patients with GHD, the increase in AChE-HS was 71% (P <0.001). VIP-immunoreactivity (VIP-IR) increased by 30% after GH treatment in patients with GHD, again reaching control values. In patients with GHD, PGP-IR did not change significantly following GH treatment. In conclusion, GH treatment of patients with GHD tends to normalize sweat gland function via sympathetic innervation. This effect is more marked in females.

UR - http://www.scopus.com/inward/record.url?scp=33747968399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747968399&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33747968399

VL - 3

SP - 130

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1096-6374

IS - SUPPL. A

ER -